AAM moves to block Connecticut’s new drug price law

The Association for Accessible Medicines (AAM) has filed for a federal injunction to prevent Connecticut from enforcing a new price-control law that it says threatens patient access to low-cost drugs and violates the US Constitution. The request was submitted October 23 in the US District Court for the District of Connecticut.

The measure, Sections 345–347 of Public Act No. 25-168, took effect in July and is due to start regulating prices in January 2026. AAM contends the statute gives Connecticut illegal authority to control drug prices across state lines and unfairly targets generic and biosimilar manufacturers rather than branded drugmakers that dominate prescription spending.

The group argues the law will reduce competition, raise costs, and drive some generics from the market. Generics currently account for around 90% of all prescriptions but only 12% of drug spending, while branded products represent the bulk of healthcare costs. AAM said its action follows a similar case in Minnesota, where a federal appeals court blocked a comparable law in June.